March 8, 2018

EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research
INDIANAPOLIS, March 8, 2018 /PRNewswire/ -- The European Foundation for the Study of Diabetes (EFSD), JDRF and Eli Lilly and Company (NYSE: LLY) have agreed to extend their collaboration for the European Programme in Type 1 Diabetes Research through 2020. The programme, which began in 2015, encourages research that advances knowledge about type 1 d...

March 6, 2018

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials
RIDGEFIELD, Conn. and INDIANAPOLIS, March 6, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to expand their clinical trial program for Jardiance® in chronic heart failure with the EMPERIAL clinical trials. These trials will evaluate the effect of Jardiance on exercise ability and heart fai...

February 26, 2018

Lilly Receives Additional FDA Approval for Verzenio™ (abemaciclib), as Initial Treatment for Advanced Breast Cancer
INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human ...

February 26, 2018

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
INDIANAPOLIS, Feb. 26, 2018 /PRNewswire/ -- Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, according to results from AWARD-10, a new Phase 3b clinical study.1 These data were published onl...

February 20, 2018

Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month
INDIANAPOLIS, Feb. 20, 2018 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) announced today findings from a Lilly-sponsored, quantitative opinion survey, which found among those surveyed, people diagnosed with migraine experienced on average 15.4 completely pain-free days over the previous 30 days. The Migraine Impact Report also highlighted the i...

Showing 1-5 of 5 Page: 1